A Phase 1 interventional study of Efinopegdutide in Non-alcoholic Steatohepatitis and Hepatic Impairment, sponsored by Merck Sharp & Dohme LLC. Completed at 4 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-22.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Merck & Co., Inc.
Among the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2023, is one of 3 in phase 1, and was the 9th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →None of the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 113 across the 10 interventional studies, 10 across the 1 observational. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the pharmacokinetics of efinopegdutide in participants with hepatic impairment compared to healthy participants, and to examine the safety and tolerability of efinopegdutide.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion and exclusion criteria include but are not limited to the following:
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with moderate hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by subcutaneous (SC) injection.
Drug: Efinopegdutide
Participants with severe hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection.
Drug: Efinopegdutide
Healthy matched participants received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection.
Drug: Efinopegdutide
Subcutaneous injection administered at a dose of 7 mg
Also known as: MK-6024, HM12525A, JNJ-64565111
Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Efinopegdutide
Blood samples collected at multiple timepoints post-dose were used to determine the AUC0-inf.
Time frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
Area Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of Efinopegdutide
Blood samples collected at multiple timepoints post-dose were used to determine the AUC0-last.
Time frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
Maximum Plasma Concentration (Cmax) of Efinopegdutide
Blood samples collected at multiple timepoints post-dose were used to determine the Cmax.
Time frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
Time to Maximum Concentration (Tmax) of Efinopegdutide
Blood samples collected at multiple timepoints post-dose were used to determine the Tmax of efinopegdutide.
Time frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
Apparent Terminal Half-life (t/12) of Efinopegdutide
Blood samples collected at multiple timepoints post-dose were used to determine the t1/2.
Time frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
Apparent Total Clearance (CL/F) of Efinopegdutide
Blood samples collected at multiple timepoints post-dose were used to determine the CL/F.
Time frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
Apparent Volume of Distribution (Vz/F) of Efinopegdutide
Blood samples collected at multiple timepoints post-dose were used to determine the Vz/F.
Time frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
Number of Participants Who Experienced an Adverse Event (AE)
An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality.
Time frame: Up to 35 days
Number of Participants Who Discontinued Study Intervention Due to an AE
An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality.
Time frame: Up to 35 days
| Milestone | Efinopegdutide in Participants With Moderate Hepatic Impairment | Efinopegdutide in Participants With Severe Hepatic Impairment | Efinopegdutide in Healthy-Matched Control Group |
|---|---|---|---|
| Started | 8 | 8 | 6 |
| Completed | 8 | 8 | 6 |
| Not completed | 0 | 0 | 0 |
Blood samples collected at multiple timepoints post-dose were used to determine the AUC0-inf.
| hr*μg/mL | Efinopegdutide in Participants With Moderate Hepatic Impairment | Efinopegdutide in Participants With Severe Hepatic Impairment | Efinopegdutide in Healthy-Matched Control Group |
|---|---|---|---|
| Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Efinopegdutide | 143 (120 to 169) | 152 (106 to 219) | 146 (81.8 to 262) |
Blood samples collected at multiple timepoints post-dose were used to determine the AUC0-last.
| hr*μg/mL | Efinopegdutide in Participants With Moderate Hepatic Impairment | Efinopegdutide in Participants With Severe Hepatic Impairment | Efinopegdutide in Healthy-Matched Control Group |
|---|---|---|---|
| Area Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of Efinopegdutide | 133 (113 to 156) | 125 (80.8 to 193) | 134 (70.2 to 255) |
Blood samples collected at multiple timepoints post-dose were used to determine the Cmax.
| μg/mL | Efinopegdutide in Participants With Moderate Hepatic Impairment | Efinopegdutide in Participants With Severe Hepatic Impairment | Efinopegdutide in Healthy-Matched Control Group |
|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Efinopegdutide | 0.348 (0.282 to 0.429) | 0.404 (0.242 to 0.675) | 0.474 (0.253 to 0.890) |
Blood samples collected at multiple timepoints post-dose were used to determine the Tmax of efinopegdutide.
| hour | Efinopegdutide in Participants With Moderate Hepatic Impairment | Efinopegdutide in Participants With Severe Hepatic Impairment | Efinopegdutide in Healthy-Matched Control Group |
|---|---|---|---|
| Time to Maximum Concentration (Tmax) of Efinopegdutide | 120.00 (96.00 to 310.93) | 72.04 (24.00 to 144.00) | 83.78 (48.00 to 167.25) |
Blood samples collected at multiple timepoints post-dose were used to determine the t1/2.
| hour | Efinopegdutide in Participants With Moderate Hepatic Impairment | Efinopegdutide in Participants With Severe Hepatic Impairment | Efinopegdutide in Healthy-Matched Control Group |
|---|---|---|---|
| Apparent Terminal Half-life (t/12) of Efinopegdutide | 146 ± 13.5 | 149 ± 26.0 | 115 ± 32.3 |
Blood samples collected at multiple timepoints post-dose were used to determine the CL/F.
| L/hr | Efinopegdutide in Participants With Moderate Hepatic Impairment | Efinopegdutide in Participants With Severe Hepatic Impairment | Efinopegdutide in Healthy-Matched Control Group |
|---|---|---|---|
| Apparent Total Clearance (CL/F) of Efinopegdutide | 0.0491 ± 16.5 | 0.0460 ± 40.8 | 0.0478 ± 60.0 |
Blood samples collected at multiple timepoints post-dose were used to determine the Vz/F.
| Liters | Efinopegdutide in Participants With Moderate Hepatic Impairment | Efinopegdutide in Participants With Severe Hepatic Impairment | Efinopegdutide in Healthy-Matched Control Group |
|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) of Efinopegdutide | 10.3 ± 17.9 | 9.88 ± 57.8 | 7.94 ± 91.7 |
An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality.
| Participants | Efinopegdutide in Participants With Moderate Hepatic Impairment | Efinopegdutide in Participants With Severe Hepatic Impairment | Efinopegdutide in Healthy-Matched Control Group |
|---|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 3 | 4 | 4 |
An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality.
| Participants | Efinopegdutide in Participants With Moderate Hepatic Impairment | Efinopegdutide in Participants With Severe Hepatic Impairment | Efinopegdutide in Healthy-Matched Control Group |
|---|---|---|---|
| Number of Participants Who Discontinued Study Intervention Due to an AE | 0 | 0 | 0 |
Collected over Up to 35 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Efinopegdutide in Participants With Moderate Hepatic Impairment | 0/8 (0%) | 1/8 (12.5%) | 2/8 (25%) |
| Efinopegdutide in Participants With Severe Hepatic Impairment | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| Efinopegdutide in Healthy-Matched Control Group | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Event | Efinopegdutide in Participants With Moderate Hepatic Impairment | Efinopegdutide in Participants With Severe Hepatic Impairment | Efinopegdutide in Healthy-Matched Control Group |
|---|---|---|---|
| Multiple injuriesInjury, poisoning and procedural complications | 1/8 | 0/8 | 0/6 |
| Event | Efinopegdutide in Participants With Moderate Hepatic Impairment | Efinopegdutide in Participants With Severe Hepatic Impairment | Efinopegdutide in Healthy-Matched Control Group |
|---|---|---|---|
| HeadacheNervous system disorders | 1/8 | 0/8 | 3/6 |
| FlatulenceGastrointestinal disorders | 0/8 | 0/8 | 2/6 |
| DyspepsiaGastrointestinal disorders | 0/8 | 1/8 | 1/6 |
| NeutropeniaBlood and lymphatic system disorders | 0/8 | 1/8 | 0/6 |
| ConstipationGastrointestinal disorders | 0/8 | 1/8 | 0/6 |
| VomitingGastrointestinal disorders | 0/8 | 1/8 | 0/6 |
| HyperbilirubinaemiaHepatobiliary disorders | 0/8 | 1/8 | 0/6 |
| Neck painMusculoskeletal and connective tissue disorders | 1/8 | 0/8 | 0/6 |
| Hepatic encephalopathyNervous system disorders | 0/8 | 1/8 | 0/6 |
| Age, Continuous(Years) | Efinopegdutide in Participants With Moderate Hepatic Impairment | Efinopegdutide in Participants With Severe Hepatic Impairment | Efinopegdutide in Healthy-Matched Control Group | Total |
|---|---|---|---|---|
| Mean | 57.5 ± 9.5 | 48.5 ± 10.5 | 56.2 ± 7.1 | 53.9 ± 9.8 |
| Sex: Female, Male(Participants) | Efinopegdutide in Participants With Moderate Hepatic Impairment | Efinopegdutide in Participants With Severe Hepatic Impairment | Efinopegdutide in Healthy-Matched Control Group | Total |
|---|---|---|---|---|
| Female | 4 | 0 | 3 | 7 |
| Male | 4 | 8 | 3 | 15 |
| Ethnicity (NIH/OMB)(Participants) | Efinopegdutide in Participants With Moderate Hepatic Impairment | Efinopegdutide in Participants With Severe Hepatic Impairment | Efinopegdutide in Healthy-Matched Control Group | Total |
|---|---|---|---|---|
| Hispanic or Latino | 6 | 7 | 6 | 19 |
| Not Hispanic or Latino | 2 | 1 | 0 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Efinopegdutide in Participants With Moderate Hepatic Impairment | Efinopegdutide in Participants With Severe Hepatic Impairment | Efinopegdutide in Healthy-Matched Control Group | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 |
| White | 8 | 8 | 5 | 21 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Nov 2023 to primary completion in Dec 2024, 12 months.
Results were first posted in Oct 2025, 10 months after primary completion.
Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 12 months is above that.
Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efinopegdutide
Non-alcoholic Fatty Liver Disease →